Assessment of effectiveness of fetal medicine foundation calculator in predicting risk for preterm preeclampsia using first trimester mean uterine artery pulsatility index and maternal factors in Indian population

Anil A, Binoj Varghese V., Afra John


Background: Preeclampsia (PE) is a hypertensive disorder of pregnancy associated with significant maternal morbidity and mortality. The outcome of the disease depends to a large extent on risk factors, maternal vascular responsiveness, screening performance and prevention effectiveness. Fetal medicine foundation has developed an online calculator that predicts the risk for PE in pregnant woman in first trimester using MUAPI (mean uterine artery pulsatility index) and maternal factors.

Methods: Diagnostic test evaluation of FMF (fetal medicine foundation) calculator done using data collected from consenting 316 women with singleton pregnancy between the gestational age 11 weeks to 14 weeks+1 day who fulfilled inclusion and exclusion criteria. All cases were followed up and results were analyzed statistically.

Results: FMF calculator predicted a high-risk population of 12 pregnant women. On follow up of 316 subjects 13 pregnant women developed preterm preeclampsia with an incidence of 4.1%. Among high-risk population 9 subjects developed preterm PE and among the 304 cases in low-risk group 4 patient developed preterm PE. In this study sensitivity of FMF calculator was 69.2% and specificity was 99% with a PPV of 75, NPV of 98.6, positive likelihood ratio of 69.9 and diagnostic odds ratio of 225. The area under ROC was 0.841 with 95% CI (0.711-0.972) was high indicating that the algorithm was able to differentiate between pregnant women at high or low risk for preterm PE.

Conclusions: This study concludes that the algorithm used in FMF calculator in first trimester is highly specific and have high sensitivity for predicting preterm PE and can be used in routine clinical practice to identify women at high risk.


Mean uterine artery pulsatility index, Preeclampsia, FMF calculator, Preterm preeclampsia

Full Text:



Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130-7.

Jeyabalan A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev. 2013;71(1).

Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24-43.

Mifsud W, Sebire NJ. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther. 2014;36(2):117-28.

Llurba E, Carreras E, Gratacós E, Juan M, Astor J, Vives A, et al. Maternal history and uterine artery doppler in the assessment of risk for development of early- and late-onset preeclampsia and intrauterine growth restriction. Obstet Gynecol Int. 2009;2009:1-6.

Stergiotou I, Crispi F, Valenzuela-Alcaraz B, Bijnens B, Gratacos E. Patterns of maternal vascular remodeling and responsiveness in early-versus late-onset preeclampsia. Am J Obstet Gynecol. 2013;209(6):558.

Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613-22.

Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51(6):743-50.

The fetal medical foundation. Fact sheet: Risk for preeclampsia. Available at: Accessed on 14 February 2022.

Phillips JK, Janowiak M, Badger GJ, Bernstein IM. Evidence for distinct preterm and term phenotypes of preeclampsia. J Matern Neonatal Med. 2010;23(7):622-6.

McCarthy FP, Ryan RM, Chappell LC. Prospective biomarkers in preterm preeclampsia: a review. Pregnancy Hypertens. 2018;14:72-8.

Tarca AL, Romero R, Benshalom-Tirosh N, Than NG, Gudicha DW, Done B, et al. The prediction of early preeclampsia: results from a longitudinal proteomics study. PLoS One. 2019;14(6):1-28.

Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008;52(5):873-80.

Ogge G, Chaiworapongsa T, Romero R, Hussein Y, Kusanovic JP, Yeo L, et al. Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med. 2011;39(6):641-52.

Wójtowicz A, Zembala-Szczerba M, Babczyk D, Kołodziejczyk-Pietruszka M, Lewaczyńska O, Huras H. Early-and late-onset preeclampsia: a comprehensive COHORT study of laboratory and clinical findings according to the new ISHHP criteria. Int J Hypertens. 2019;2019.

Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374(9694):979-88.

Excellence NI for H and C. Hypertension in pregnancy: diagnosis and management. Am J Obs Gynecol. 2010;77(1):1-22.

Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International federation of gynecology and obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynecol Obstetr. 2019;145:1-33.

Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8-15.

O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016;214(1):103.

Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol. 2015;213(1):62.

Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First-trimester markers for the prediction of preeclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol. 2010;35(6):671-9.

Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51(6):743-50.

Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, et al. ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm. Ultrasound Obstet Gynecol. 2018;51(6):738-42.

Wright A, Wright D, Syngelaki A, Georgantis A, Nicolaides KH. Two-stage screening for preterm preeclampsia at 11-13 weeks’ gestation. Am J Obstet Gynecol. 2019;220(2):197.

Gestational hypertension and preeclampsia: acog practice bulletin summary, number 222. Obstet Gynecol. 2020;135(6):1492-5.

DiLorenzo G, Ceccarello M, Cecotti V, Ronfani L, Monasta L, Brumatti LV, et al. First trimester maternal serum PIGF, free β-hCG, PAPP-A, PP-13, uterine artery Doppler and maternal history for the prediction of preeclampsia. Placenta. 2012;33(6):495-501.

Odibo AO, Zhong Y, Goetzinger KR, Odibo L, Bick JL, Bower CR, et al. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia. Placenta. 2011;32(8):598-602.

Acharya DR. Prediction of preeclampsia by waist circumference and by mean arterial pressure. Int J Med Biomed Stud. 2019;3(10):24-7.

Mayrink J, Souza RT, Feitosa FE, Rocha Filho EA, Leite DF, Vettorazzi J, et al. Mean arterial blood pressure: Potential predictive tool for preeclampsia in a cohort of healthy nulliparous pregnant women. BMC Pregnancy Childbirth. 2019;19(1):1-8.

Poon LCY, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11-13 weeks’ ’estation. Fetal Diagn Ther. 2012;31(1):42-8.

Wright A, Wright D, Ispas CA, Poon LC, Nicolaides KH. Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45(6):698-706.

Gómez O, Figueras F, Fernández S, Bennasar M, Martínez JM, Puerto B, et al. Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation. Ultrasound Obstet Gynecol. 2008;32(2):128-32.

Velauthar L, Plana MN, Kalidindi M, Zamora J, Thilaganathan B, Illanes SE, et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55 974 women. Ultrasound Obstet Gynecol. 2014;43(5):500-7.

Gómez O, Martínez JM, Figueras F, DelRío M, Borobio V, Puerto B, et al. Uterine artery Doppler at 11-14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol. 2005;26(5):490-4.

Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, et al. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol. 2010;203(4):383.